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Abstract: A reliable method for spectrophotometric determination of urinary malondialdehyde (MDA), according to the thiobarbituric acid 
(TBA) assay, is described. To account for matrix interference and differences in individual urine composition, standard addition procedure was 
applied. The method is adequately selective (LoQ = 0.09 μM in the presence of 0.1 M creatinine and 0.5 M urea) and reliable (within-day and 
between-day variability of less than 5 %). The mean level of urinary MDA was 1.52 ± 0.73 µM that is in good agreement with spectrofluorometric 
determination (1.20 ± 0.56 μM; p = 0.085) as well as with previous studies that used HPLC. Furthermore, it is demonstrated that MDA is stabile 
in urine at room temperature for 24 h and when stored at –20 °C for 6 months. The described method enables simple, rapid and cost-effective 
determination of urinary MDA as a relevant and non-invasive marker of “whole-body” oxidative stress. 
 





HE dicarbonyl malondialdehyde (MDA) is one of the 
products of lipid peroxidation.[1,2] Lipid peroxidation is 
a process in biological systems initiated by an attack of re-
active oxygen species (ROS) on polyunsaturated fatty acids, 
major constituents of plasma membranes. The first prod-
ucts of lipid peroxidation are unstable lipid peroxides that 
are further converted by consecutive reactions of oxida-
tion, rearrangements and scission into more stable car-
bonyl compounds, among which is MDA.[2,3] 
 The condition of imbalance between the metabolic 
production of reactive species and the cellular ability to 
scavenge the reactive metabolites or repair the incurred 
damage is oxidative stress. This condition is connected to 
the development of various diseases, including cancer.[3,6] 
Therefore, it is important to find reliable markers to follow 
the extent of oxidative stress. The level of MDA as a final 
product of lipid peroxidation in specific tissue is considered 
as a marker of oxidative stress in that particular tissue, and 
MDA level in plasma and urine represents “whole-body” 
oxidative stress.[4,7] Drury at al.[4] demonstrated by com-
paring plasma and urine samples that urinary MDA level is 
good marker of “whole-body” oxidative stress in popula-
tions without renal disease.  
 Considering that urine has several practical ad-
vantages over plasma (urine is easier to collect, and collec-
tion is readily accepted by participants of epidemiological 
studies), the aim of this study was to set a reliable and rapid 
method for determination of MDA in urine as a relevant 
and non-invasive marker of “whole-body” oxidative stress. 
This study seems particularly relevant due to the emerging 
importance of urine as ideal source of biomarkers that can 
reflect early-stage systemic changes.[8] Recently published 
methods for determination of MDA in urine are employing 
HPLC, LC-MS/MS, GC-MS/MS or chemiluminescence.[9–12] 
These methods are time-consuming and not particularly 
suitable for automatization that is especially important in 
studies with large number of samples. Moreover, the re-
quired equipment is not readily available in laboratories 
worldwide, particularly in developing countries. Therefore, 
spectrophotometric and spectrofluorometric methods  
for the determination of MDA are revisited in this study as 
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application of the methods described in this study on 
microplate readers could easily provide a much higher 




Chemicals and Standard Preparation 
Chemicals 2-thiobarbituric acid (TBA), o-phosphoric acid  
(o-H3PO4), urea and creatinine were from Kemika, Zagreb, 
Croatia. 1,1,3,3-tetraethoxypropane (malondialdehyde bis-
dimethylacetal) (Sigma, St. Louis, MO, USA) was used as 
MDA standard. All chemicals were of p.a. grade and used 
without further purification. 
 MDA stock solution (in concentration of 3.0 M) was 
prepared by diluting MDA standard in MilliQ water. MDA 
stock solution was stored in aliquots at –20 °C. Working 
standards in MilliQ water (ranging from 0.1 to 10.11 μM) 
were prepared fresh daily. 
Equipment 
Spectrophotometric measurements were performed on 
Agilent 8453 UV-Vis spectrophotometer equipped with UV-
Visible ChemStation software (Agilent Technologies, CA, 
USA) for data collection and analysis. Spectra were rec-
orded at room temperature in quartz cuvettes with 1 cm 
path length. 
Fluorescence spectra were measured at 25 °C by 
OLIS RSM 1000F spectrofluorometer (Olis Inc., Bogart, 
Georgia, USA), equipped with a thermostatted cell holder 
and OLIS Globalworks software for data collection and anal-
ysis. Fluorescence units (f. u.) are given as a ratio of signals 
obtained from sample and reference photomultiplier 
tubes. Spectra were recorded at room temperature in 
quartz cuvettes with 1 cm excitation path length and 0.2 cm 
emission path length. Each reported spectrum (or single-
wavelength fluorescence) is an average of 10 000 rapid-
scan fluorescence measurements collected in 10 seconds. 
Sample Collection and Preparation 
Urine spot samples from healthy volunteers of both gen-
ders were collected in sterile containers. Testing of the 
method was performed on n = 10 urine samples. For testing 
the stability of MDA in urine at room temperature, addi-
tional urine samples (n = 5) were collected and the level of 
MDA in the same sample was monitored for 24 hours. For 
testing the stability of MDA in urine at –20 °C, urine samples 
(n = 7) were collected and stored in aliquots, followed by 
monitoring the level of MDA in intervals throughout 6 
months. The study was approved by the Ethics Committee 
for Experimentation of Faculty of Pharmacy and Biochem-
istry, University of Zagreb, and observed the ethical princi-
ples of the Declaration of Helsinki.  
 Sample preparation procedure for determination of 
MDA in urine was as follows: to 400 µl of urine 250 µl of 
TBA (0.6 %) and 750 µl o-H3PO4 (1 %) were added. The re-
action mixture was heated at 90 °C for 30 min in a temper-
ature-controlled heating block (G-Term 035, Fratelli Galli, 
Milano, Italy). Reaction (Figure 1) was stopped by placing 
samples on ice. The MDA concentration was measured 
spectrophotometrically at λ = 532 nm (A532) and spectro-
fluorometrically at λem = 553 nm (λex = 515 nm; F553). 
 Since essentially no urine sample is MDA-free, MDA 
concentration was determined by standard addition proce-
dure.[13] Urine composition varies due to differences in in-
dividual water balance, environmental conditions, physical 
exercise and nutrition[14] and the standard addition method 
provides reasonable means to account for possible matrix 
interference effects, i.e. recovery.[15] For each urine sample, 
a total of 4 samples were prepared for measurement as fol-
lows: blank sample (no reagent added), test sample and 
two additional test samples with added known concentra-
tion of MDA at two levels (Table 1). The signal value for the 
blank sample has been subtracted from the samples with 
added reagent, thus accounting for baseline interferences. 
All samples underwent same sample preparation proce-
dure described above. Results were expressed as mi-
cromoles per liter (µM). 
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Data are expressed as mean ± standard deviation. Statisti-
cal analysis of the data (descriptive statistics and linear re-
gression) was performed with Statistica 8.0 software (Stat 
Soft Ltd., Bedford, UK). Paired t-test was used to analyze 
differences between methods and samples. Differences 
were considered significant for values of two-tail p < 0.05. 
 
RESULTS AND DISCUSSION 
Sample Preparation and Testing for 
Possible Interferences 
MDA in reaction with TBA (TBA assay) forms an intensely 
colored adduct (MDA-TBA2; Figure 1) that is easily assessed 
spectrophotometrically or spectrofluorometrically, and 
therefore, the method is frequently used to follow extent 
of lipid peroxidation in biological samples.[3,4] The reaction 
of MDA and TBA depends on temperature and pH, but too 
strong acid and high temperature (so-called “harsh condi-
tions”) can lead to overestimation of results due to artefac-
tual peroxidation of sample constituents.[16] In this study 
the reaction mixture was heated at 90 °C for 30 minutes, 
since the experimental data indicate that these conditions 
yield maximal product formation (Figure 2). 
 Literature references also indicate that the TBA as-
say lacks selectivity: TBA is reacting not only with MDA, but 
also with other components of biological samples, such as 
sugars, amino acids, bilirubin and albumin.[3,17] To avoid 
false-positive results and overestimation of MDA levels, use 
of HPLC is suggested, but that prolongs the duration of 
analysis and increases its cost. Therefore, in this study, pos-
sible interferences for spectrophotometric and spectro-
fluorometric determination of MDA levels in urine were 
tested. According to the literature, possible interferences 
for urinary MDA determination are creatinine and 
urea.[18,19] Creatinine and urea were prepared in concentra-
tions higher than expected in human urine, i.e. values 
higher than normal (100 mM vs. 16 mM and 0.5 M vs. 0.39 
M for creatinine and urea, respectively),[14,19] and under-
went the same sample preparation procedure as described 
for urine samples. The spectra shown in Figure 3 indicate 
Table 1. Sample preparation for sample addition procedure 
Sample V(urine) / μl V(o-H3PO4, 1 %) / μl V(TBA, 0.6 %) / μl V(MilliQ water) / μl V(Standard)(a) / μl 
Blank 400 750 - 260 - 
Reagent 400 750 250 10 - 
Standard level 1 400 750 250 5 5 
Standard level 2 400 750 250 - 10 
(a) Working standard 0.3035 mM solution was prepared fresh daily by diluting MDA stock solution (c = 3.0 M) in MilliQ water. 
 
 
Figure 2. Derivatization rate of malondialdehyde (MDA) 
standard in MilliQ water (c = 6.07 μM) and 2-thiobarbituric 




Figure 3. Spectra of MDA standard in MilliQ water in the 
presence of 0.1 M creatinine and 0.5 M urea obtained:  
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that, in fact, urea and creatinine do not significantly inter-
fere with spectrophotometric or spectrofluorometric de-
termination of MDA-TBA2 adduct. 
Validation of the Method 
Linearity of the method was tested using MDA standards 
prepared both in MilliQ water or urine, in the concentration 
range from 0.5 to 10.11 μM (spectrophotometry) or 0.5 to 
6.07 μM (spectrofluorometry). All calibration curves were 
linear for both methods and either sample type (Figure 4). 
Parameters of method validation with MDA standards  
prepared in MilliQ water are given in Table 2. The repeata-
bility (within-day variability) was evaluated by determining 
MDA level at three different concentrations, five repeti-
tions each. Mean coefficient of variation (CV) for within-day 
repetition was 3.76 % and 2.72 % for spectrophotometric 
and spectrofluorometric determination, respectively. The 
reproducibility (between-day variability) was tested by 
measuring MDA level of same MDA standard daily for 6 
consecutive days. Between-day variability CV was 4.39 % 
and 4.27 % for spectrophotometric and spectrofluoromet-
ric determination, respectively.  
 
      
      
Figure 4. Calibration curves of MDA standard: spectrophotometric determination (λ = 532 nm) in MilliQ water (a); 
spectrophotometric determination (λ = 532) in urine (b); spectrofluorometric determination (λem = 553 nm (λex = 515 nm)) in 
MilliQ water (c); spectrofluorometric determination (λem = 553 nm (λex = 515 nm)) in urine (d). Linear regression parameters 
are given on each plot. 
Table 2. Validation parameters of spectrophotometric and spectrofluorometric determination of MDA in urine gained with 
MDA standards prepared in MilliQ water. LoD and LoQ values are given in the presence of 0.1 M creatinine and 0.5 M urea 
Parameter Spectrophotometric Spectrofluorometric 
Within-day variability, CV / % 3.76 2.72 
Between-day variability, CV / % 4.39 4.27 
Limit of detection, LoD / µM 0.03 0.10 
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 Special care was taken in estimation of limit of de-
tection (LoD) and limit of quantification (LoQ) values. For 
this purpose, an additional calibration was performed in 
MilliQ water in the range from 0.1 to 1 μM, in the presence 
of 0.1 M creatinine and 0.5 M urea (Figure 5), in order to 
account for possible interferences. The values were calcu-
lated as LoD = 3.3 sy / a, and LoQ = 10 sy / a, where sy is the 
standard deviation of the linear regression intercept, and a 
is the linear regression slope. The results of LoQ and LoD 
determination are given in Table 2. Unexpectedly, the spec-
trophotometric method was found to be more sensitive 
(approximately 3-fold lower values of LoD and LoQ), which 
can be attributed to the rapid-scanning fluorescence meas-
urement technique that was chosen for speed (only 10 sec-
onds per sample). Additionally, the fluorescence signal 
apparently deviates from linearity for [MDA] < 0.2 µM in 
the presence of 0.1 M creatinine and 0.5 M urea (Figure 
5b), which is also reflected in the higher value of LoQ = 0.3 
µM vs. LoQ = 0.09 µM for absorbance. 
Urine Samples 
The levels of MDA in urine samples (n = 10; adults, both 
genders, average age 30.8 ± 14.13 years, range 21 – 58) de-
termined spectrophotometrically were in the range from 
0.59 to 2.36 µM and mean level was 1.52 ± 0.73 µM. The 
same samples were analyzed spectrofluorometrically and 
similar results were obtained, with MDA levels in the range 
from 0.66 to 2.03 μM and mean level of 1.20 ± 0.56 μM. The 
values obtained by the two methods were not significantly 
different (p = 0.085). Representative calibration curves for 
urine samples obtained spectrophotometrically or spectro-
fluorometrically by the sample addition method are given 
in Figure 6. 
 In a previous study by Drury et al.[4] urinary MDA 
level of preterm infants (n = 50) was in the range from 0.5 
to 2.5 µM, determined by HPLC with UV-Vis detector. In an 
epidemiological study conducted on 44 Chinese volunteers 
(22 children and their mothers; average 23.4 years old, 
range 10 – 46), mean MDA level in urine was 1.52 ± 0.20 µM, 
determined by HPLC with fluorescent (FL) detector.[20] In 
the same study, when testing the stability of MDA in urine 
(at –20 °C for 16 h) mean level of MDA in urine of 10 subjects 
was as high as 2.43 ± 0.19 µM. In another epidemiological 
study that included 500 urine samples collected in Korea 
(including adults, primary and middle school students, and 
infants), MDA in urine was assessed by HPLC with FL detec-
tor and mean MDA concentration was 2.15 ± 1.6 µM (range 
from 0.01 to 11.86 µM).[21] The values for MDA levels in 
urine reported in this study are in good agreement with the 
previous studies that employed HPLC separation methods 
for MDA determination (Table 3). The results for urinary 
MDA obtained spectrophotometrically were additionally 
verified spectrofluorometrically. These results indicate that 
the described spectrophotometric method can be used for 
determination of MDA in urine in order to follow the extent 
of “whole-body” oxidative stress. The method is particu-
larly suitable for epidemiological studies, in which fast and 
reliable determination of MDA in a large number of sam-
ples is required. 
Stability of MDA in Urine Samples 
In epidemiological studies a large number of samples are 
collected and stored; therefore it was important to verify 
the stability of MDA in stored urine samples. Kumar et al.[22] 
observed that MDA is unstable when stored at –20 °C for 
longer than three weeks, with an observed increase of MDA 
level in plasma stored for 1 month to 1 year. Lee and 
Kang[20] showed that MDA is stable in urine at room tem-
perature and at –20 °C for 16 hours. In this study, the sta-
bility of MDA in urine was assessed at room temperature 
for 24 h and when stored at –20 °C for 6 months. To test 
MDA stability at room temperature, MDA level in urine 
samples (n = 5) was assessed immediately after collection, 
Figure 5. Calibration curves of MDA standard in MilliQ water 
for determination of LoD and LoQ values in the presence of 
0.1 M creatinine and 0.5 M urea: spectrophotometric 
determination (λ = 532 nm) (a); spectrofluorometric 
determination (λem = 553 nm (λex = 515 nm)) (b). Linear 
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and 1, 2 and 24 h afterwards. The absorbance signal (A532) 
of TBA-treated urine samples kept at room temperature for 
24 h was not significantly changed (p = 0.39) (Figure 7a). 
Similarly, no significant change in A532 of TBA-treated urine  
 
samples (n = 7) stored at –20 °C for up to 6 months (3 – 180 
days) was observed (p = 0.81) (Figure 7b). 
 
CONCLUSION 
This study describes a spectrophotometric method for sim-
ple, rapid and cost-effective determination of MDA in urine 
that is particularly suitable to studies that include a large 
number of samples. Testing for interferences demon-
strated that the spectrophotometric method is adequately 
selective (LoQ = 0.09 μM in the presence of 0.1 M creatinine 
and 0.5 M urea) and reliable (within-day and between-day 
variability of less than 5 %). The obtained results were ad-
ditionally confirmed spectrofluorometrically, and the val-
ues of MDA levels are in good agreement with previous  
 
Table 3. Comparison of the MDA levels in human urine reported previously obtained by HPLC methods and the described 




Range / µM Mean value / µM Method 
This study n = 10 0.59 – 2.36 1.52 ± 0.73 UV/Vis 
This study n = 10 0.66 – 2.03 1.20 ± 0.56 FL 
Drury et al.[4] n = 50 0.5 – 2.5 – HPLC-UV/Vis 
Lee and Kang[20] n = 10 – 2.43 ± 0.19 HPLC-FL 
Lee and Kang[20] n = 44 – 1.52 ± 0.20 HPLC-FL 




Figure 6. Representative calibration curves for urine 
samples obtained by the sample addition method. The 
concentrations of added standard are given on the x-axis: 
spectrophotometric method (a); spectrofluorometric 
method (b). Linear regression parameters are given on each 
plot. The concentration of MDA in the urine sample was 
then calculated as [MDA] = – b / a, where b and a are the 
intercept and the slope of the regression line (0.86 µM and 





Figure 7. Stability of MDA in urine samples: 24-hour study of 
samples stored at room temperature (a); 6-month study of 
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studies performed with HPLC separation of MDA-TBA2 
adduct. Furthermore, it is demonstrated that MDA is stabile 
in urine at room temperature for 24 h and when stored at 
–20 °C for 6 months. 
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